Last reviewed · How we verify

ropivacaine,morphine chloride,epinephrine,ketorolac

Jose Antonio Bernia Gil · FDA-approved active Small molecule

ropivacaine,morphine chloride,epinephrine,ketorolac is a Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic) Small molecule drug developed by Jose Antonio Bernia Gil. It is currently FDA-approved for Perioperative pain management and local anesthesia.

This is a combination analgesic and anesthetic formulation that blocks nerve conduction (ropivacaine), activates opioid receptors (morphine), increases sympathetic tone (epinephrine), and inhibits prostaglandin synthesis (ketorolac) to provide multimodal pain relief and local anesthesia.

This is a combination analgesic and anesthetic formulation that blocks nerve conduction (ropivacaine), activates opioid receptors (morphine), increases sympathetic tone (epinephrine), and inhibits prostaglandin synthesis (ketorolac) to provide multimodal pain relief and local anesthesia. Used for Perioperative pain management and local anesthesia.

At a glance

Generic nameropivacaine,morphine chloride,epinephrine,ketorolac
SponsorJose Antonio Bernia Gil
Drug classMultimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic)
TargetSodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac)
ModalitySmall molecule
Therapeutic areaPain Management / Anesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing pain signal transmission. Morphine acts as a mu-opioid receptor agonist to provide systemic analgesia. Epinephrine causes vasoconstriction to prolong local anesthetic duration and reduce systemic absorption. Ketorolac is a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes to reduce inflammatory pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ropivacaine,morphine chloride,epinephrine,ketorolac

What is ropivacaine,morphine chloride,epinephrine,ketorolac?

ropivacaine,morphine chloride,epinephrine,ketorolac is a Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic) drug developed by Jose Antonio Bernia Gil, indicated for Perioperative pain management and local anesthesia.

How does ropivacaine,morphine chloride,epinephrine,ketorolac work?

This is a combination analgesic and anesthetic formulation that blocks nerve conduction (ropivacaine), activates opioid receptors (morphine), increases sympathetic tone (epinephrine), and inhibits prostaglandin synthesis (ketorolac) to provide multimodal pain relief and local anesthesia.

What is ropivacaine,morphine chloride,epinephrine,ketorolac used for?

ropivacaine,morphine chloride,epinephrine,ketorolac is indicated for Perioperative pain management and local anesthesia.

Who makes ropivacaine,morphine chloride,epinephrine,ketorolac?

ropivacaine,morphine chloride,epinephrine,ketorolac is developed and marketed by Jose Antonio Bernia Gil (see full Jose Antonio Bernia Gil pipeline at /company/jose-antonio-bernia-gil).

What drug class is ropivacaine,morphine chloride,epinephrine,ketorolac in?

ropivacaine,morphine chloride,epinephrine,ketorolac belongs to the Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic) class. See all Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic) drugs at /class/multimodal-analgesic-combination-local-anesthetic-opioid-nsaid-sympathomimetic.

What development phase is ropivacaine,morphine chloride,epinephrine,ketorolac in?

ropivacaine,morphine chloride,epinephrine,ketorolac is FDA-approved (marketed).

What are the side effects of ropivacaine,morphine chloride,epinephrine,ketorolac?

Common side effects of ropivacaine,morphine chloride,epinephrine,ketorolac include Nausea, Dizziness, Hypotension, Tachycardia, Local injection site reactions.

What does ropivacaine,morphine chloride,epinephrine,ketorolac target?

ropivacaine,morphine chloride,epinephrine,ketorolac targets Sodium channels (ropivacaine), mu-opioid receptors (morphine), alpha/beta-adrenergic receptors (epinephrine), cyclooxygenase 1 and 2 (ketorolac) and is a Multimodal analgesic combination (local anesthetic + opioid + NSAID + sympathomimetic).

Related